Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 85Lymphoma, Follicular 53Lymphoma 50Lymphoma, Non-Hodgkin 47Lymphoma, Mantle-Cell 45Lymphoma, B-Cell, Marginal Zone 45Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, B-Cell 31Recurrence 20Burkitt Lymphoma 20Waldenstrom Macroglobulinemia 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms 16Leukemia 11Leukemia, Hairy Cell 7Lymphoproliferative Disorders 5Hodgkin Disease 5Hematologic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Dendritic Cell Sarcoma, Interdigitating 4Neoplasm, Residual 3Lymphoma, AIDS-Related 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Epstein-Barr Virus Infections 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Vincristine 1Valganciclovir 1Therapeutics 1Rituximab 1Prednisone 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Phacoemulsification 1Lenalidomide 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intraocular Lymphoma × Rituximab × 1 year × Clear all
NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

University of Chicago

Phase 1/2 Completed
55 enrolled 17 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡